MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer

Supportive Care in Cancer

Volumn 21, Issue 4, 2013, Pages 1153-1156

  Engin, Hüseyin ^a   Bilir, Cemil ^a   Üstündağ, Yücel ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Ascites; Malignancy; MELD sodium; Survival

Indexed keywords

FUROSEMIDE; SPIRONOLACTONE;

ABDOMINAL PAIN; ABDOMINAL SWELLING; ADULT; ANOREXIA; ARTICLE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT ASCITES; MODEL FOR END STAGE LIVER DISEASE SODIUM SCORE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PARACENTESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STOMACH CANCER; VOMITING; WEIGHT GAIN;

EID: 84879757079     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1640-3     Document Type: Article

References (22)

1. Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945-949
2. Parsons SL, Watson SA, Steele RJ (1996) Malignant ascites [review]. Br J Surg 83:6-14
3. Runyon BA, Hoefs JC, Morgan TR (1988) Ascitic fluid analysis in malignancy-related ascites. Hepatology 8:1104-1109
4. Shukuya T, Yasui H, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N (2010) Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol 40:1135-1138
5. Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198:999-1011
6. Chang DK, Kim JW, Kim BK, Lee KL, Song CS, Han JK, Song IS (2005) Clinical significance of CT-defined minimal ascites in patients with gastric cancer. World J Gastroenterol 11:6587-6592
7. Zervos EE, Osborne D, Boe BA, Luzardo G, Goldin SB, Rosemurgy AS (2006) Prognostic significance of new onset ascites in patients with pancreatic cancer. World J Surg Oncol 4:16
8. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464-470
9. Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, Chiang JH, Chiou YY, Lui WY, Lee PC, Lee SD (2008) The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 40:882-889
10. Kim JH, Kim JH, Choi JH, Kim CH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS (2009) Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Scand J Gastroenterol 44:346-357
11. Gastrointestinal Tumor Study Group (2006) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987:59
12. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL (2000) A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 95:17-31
13. Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A (2002) Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 86:669
14. Shimizu Y, Sano T, Yasui K (2007) Predicting pleural effusion and ascites following extended hepatectomy in the non-cirrhotic liver. J Gastroenterol Hepatol 22(6):837-840
15. Weston BR, Ross WA, Wolff RA, Evans D, Lee JE, Wang X, Xiao LC, Lee JH (2008) Rate of bilirubin regression after stenting in malignant biliary obstruction for the initiation of chemotherapy: how soon should we repeat endoscopic retrograde cholangiopancreatography? Cancer 112:2417-2423
16. Martin JA, Slivka A, Rabinovitz M, Carr BI, Wilson J, Silverman WB (1999) ERCP and stent therapy for progressive jaundice in hepatocellular carcinoma: which patients benefit, which patients don't? Dig Dis Sci 44:1298-1302
17. Nakamura Y, Tsuchiya K, Nitta K, Ando M (2011) Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality. Nihon Jinzo Gakkai Shi 53(1):38-45
18. Addario L, Tritto G, Cavaglià E, Amodio F, Giannelli E, Di Costanzo GG (2011) Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. Dig Liver Dis 43:319-324
19. Nakajo A, Hokita S, Ishigami S et al (2008) A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol 62:1103-1109
20. Doi T, Muro K, Boku N et al (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28:1904-1910
21. Javle MM, Shroff RT, Xiong H et al (2010) Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10:368
22. Moini M, Hoseini-Asl MK, Taghavi SA et al (2011) Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation. Clin Transplant 25:638-645